Toboroz
ISEE-RCC study
2024-514181-39-00· 3. fázis· Stichting Radboud universitair medisch centrum· Forrás
Toboroz
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289· 3. fázis· Takeda· Forrás
Toboroz
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
NCT06623890· Biogen· Forrás
Contact: Bart van de Warrenburg (principal investigator)
Toboroz
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Még nem toboroz
The effect of Oxygen sUppleTion on vascular resistance and FLOW: the OUTFLOW study
2024-516279-34-00· 4. fázis· Stichting Radboud universitair medisch centrum· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220· 3. fázis· Genmab· Forrás
Toboroz
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)
NCT04909684· 3. fázis· Stichting Radboud universitair medisch centrum· Forrás
Fut, nem toboroz
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178· 3. fázis· Genmab· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333· 2. fázis· AskBio Inc· Forrás
Toboroz
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
NCT06016946· Friedreich's Ataxia Research Alliance· Forrás
Contact: Judith van Gaalen
Toboroz
Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study
NCT06320626· 4. fázis· Universitair Medisch Centrum Utrecht· Forrás
Toboroz
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850· 1/2. fázis· Blue Earth Therapeutics Ltd· Forrás
Fut, nem toboroz
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05083169· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136· 2. fázis· Mirum Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986· 2. fázis· Travere Therapeutics, Inc.· Forrás
Fut, nem toboroz
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
NCT04949113· 3. fázis· The Netherlands Cancer Institute· Forrás
Fut, nem toboroz
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
NCT04794101· 3. fázis· MeiraGTx Ocular UK Ltd· Forrás
Fut, nem toboroz
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· 3. fázis· Actelion· Forrás
Fut, nem toboroz
EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study
NCT03517137· 2. fázis· European Organisation For Research And Treatment Of Cancer· Forrás
Fut, nem toboroz
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM
NCT03673826· 2. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Toboroz
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340· 1/2. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506· 3. fázis· Gilead Sciences· Forrás
Toboroz
DRUP trial
NCT02925234· 2. fázis· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
NCT02362594· 3. fázis· Merck Sharp & Dohme LLC· Forrás